Apabetalone, also known as RVX-208, is a potent inhibitor of BET bromodomains. RVX-208 functions by removing atherosclerotic plaque via reverse cholesterol transport (RCT). RVX-208 increases the production of ApoA-I in hepatocytes in vitro, and in vivo in monkeys and humans, which results in increased HDL-C, but the molecular target was not previously reported. RVX-208 may be a promising new approach to the treatment of atherosclerosis.
Chemical Properties:
Boiling point: 594.2±60.0 °C(Predicted)
density: 1.28±0.1 g/cm3(Predicted)
pka: 14.21±0.10(Predicted)
Epigenetic Reader Domain Inhibitors Related Products:
ICG-001; (+)-JQ1; I-BET151; PFI-1; Molibresib; C646; Curcumin; Bromosporine; Birabresib; UNC1215; GSK6853; CPI-637; BI-9564; PFI-4; XMD8-92; MS436; CPI-203; KG-501; Mivebresib; GSK2801